Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.

IF 2.6 4区医学 Q3 CELL BIOLOGY Analytical Cellular Pathology Pub Date : 2020-07-31 eCollection Date: 2020-01-01 DOI:10.1155/2020/2563208

Xujian Liu, Qianqian Zhang, Yi Zhao, Jianjun Xun, Hongzeng Wu, Helin Feng

{"title":"Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.","authors":"Xujian Liu, Qianqian Zhang, Yi Zhao, Jianjun Xun, Hongzeng Wu, Helin Feng","doi":"10.1155/2020/2563208","DOIUrl":null,"url":null,"abstract":"Background: JMJD2B has been reported to be implicated in malignant tumors. This study is aimed at exploring the expression and prognostic significance of JMJD2B in osteosarcoma and its association with hypoxia-inducible factor 1 (HIF1).Methods: The histopathological and clinical characteristics were retrospectively reviewed from 53 osteosarcoma patients. JMJD2B and HIF1 were examined by immunohistochemical staining of paraffin-embedded osteosarcoma samples, and their association with clinical characteristics was examined by Spearman's test. Overall survival was examined by Kaplan-Meier analysis, and prognostic factors were identified by univariate and multivariate regression analyses.Results: JMJD2B and HIF1 expression levels were both significantly associated with Enneking stage, distant metastasis, and neoadjuvant chemotherapy, and the JMJD2B and HIF1 expressions were positively correlated (p < 0.001, R = 0.752). In addition, univariate analysis showed that the expression of both JMJD2B and HIF1 was significantly associated with overall survival, but multivariate analysis showed that only JMJD2B expression was significantly associated with overall survival in osteosarcoma patients.Conclusions: JMJD2B and HIF1 expression levels show significant correlation with osteosarcoma progression, and JMJD2B could predict poor prognosis of osteosarcoma patients.","PeriodicalId":49326,"journal":{"name":"Analytical Cellular Pathology","volume":"2020 ","pages":"2563208"},"PeriodicalIF":2.6000,"publicationDate":"2020-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2563208","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical Cellular Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2020/2563208","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 7

Abstract

Background: JMJD2B has been reported to be implicated in malignant tumors. This study is aimed at exploring the expression and prognostic significance of JMJD2B in osteosarcoma and its association with hypoxia-inducible factor 1 (HIF1).

Methods: The histopathological and clinical characteristics were retrospectively reviewed from 53 osteosarcoma patients. JMJD2B and HIF1 were examined by immunohistochemical staining of paraffin-embedded osteosarcoma samples, and their association with clinical characteristics was examined by Spearman's test. Overall survival was examined by Kaplan-Meier analysis, and prognostic factors were identified by univariate and multivariate regression analyses.

Results: JMJD2B and HIF1 expression levels were both significantly associated with Enneking stage, distant metastasis, and neoadjuvant chemotherapy, and the JMJD2B and HIF1 expressions were positively correlated (p < 0.001, R = 0.752). In addition, univariate analysis showed that the expression of both JMJD2B and HIF1 was significantly associated with overall survival, but multivariate analysis showed that only JMJD2B expression was significantly associated with overall survival in osteosarcoma patients.

Conclusions: JMJD2B and HIF1 expression levels show significant correlation with osteosarcoma progression, and JMJD2B could predict poor prognosis of osteosarcoma patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

JMJD2B和缺氧诱导因子1表达与骨肉瘤预后不良的关系

背景:已有报道称JMJD2B与恶性肿瘤有关。本研究旨在探讨JMJD2B在骨肉瘤中的表达、预后意义及其与缺氧诱导因子1 (HIF1)的关系。方法:回顾性分析53例骨肉瘤患者的组织病理及临床特点。石蜡包埋骨肉瘤标本免疫组化染色检测JMJD2B和HIF1, Spearman试验检测其与临床特征的相关性。Kaplan-Meier分析检查总生存率，单因素和多因素回归分析确定预后因素。结果:JMJD2B和HIF1表达水平与Enneking分期、远处转移、新辅助化疗均有显著相关，且JMJD2B和HIF1表达水平呈正相关(p < 0.001, R = 0.752)。此外，单因素分析显示，JMJD2B和HIF1的表达均与总生存期显著相关，但多因素分析显示，在骨肉瘤患者中，只有JMJD2B的表达与总生存期显著相关。结论:JMJD2B和HIF1表达水平与骨肉瘤进展有显著相关性，JMJD2B可预测骨肉瘤患者预后不良。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Analytical Cellular Pathology ONCOLOGY-CELL BIOLOGY

CiteScore

4.90

自引率

3.10%

发文量

审稿时长

16 weeks

期刊介绍： Analytical Cellular Pathology is a peer-reviewed, Open Access journal that provides a forum for scientists, medical practitioners and pathologists working in the area of cellular pathology. The journal publishes original research articles, review articles, and clinical studies related to cytology, carcinogenesis, cell receptors, biomarkers, diagnostic pathology, immunopathology, and hematology.